Business Context and Reporting Period
This Form 6-K filing by Immatics N.V. was submitted on October 10, 2024. The report provides updated Phase 1b clinical data for IMA203, a TCR-T cell therapy targeting PRAME in melanoma patients, with a data cutoff of August 23, 2024. It also outlines the design and timeline for SUPRAME, the upcoming Phase 3 registration-enabling trial.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development progress, safety data, and regulatory milestones.
Material Changes and Clinical Updates
- Anti-Tumor Activity: In the Phase 1b melanoma population (N=28), the confirmed Objective Response Rate (ORR) was 54% (14/26), with a Disease Control Rate of 92%. Median Progression-Free Survival (PFS) was 6.0 months, and Median Overall Survival (OS) was not reached.
- Improvement Over Prior Data: Compared to Phase 1a patients, Phase 1b patients showed a significant positive shift in outcomes, with median PFS increasing from 2.6 months to 6.0 months and median OS improving from 6.3 months to not reached. This improvement is attributed to manufacturing updates including T cell enrichment processes.
- Safety Profile: In the safety population (N=70), Grade 3+ treatment-emergent adverse events were observed, primarily expected cytopenias and mild-to-moderate cytokine release syndrome (CRS). No Grade 5 treatment-related adverse events were observed.
- Translational Data: IMA203 T cells demonstrated rapid engraftment and persistence of over two years. T cell dose was significantly associated with clinical responses (p=0.02).
Guidance, Outlook, and Risks
- Regulatory Milestones: Immatics completed a Type D meeting with the FDA on September 24, 2024, confirming the Recommended Phase 2 Dose (RP2D) and the design for the SUPRAME Phase 3 trial. A meeting with the German Paul Ehrlich Institute (PEI) confirmed the same design for Germany.
- Phase 3 Trial (SUPRAME): The trial will evaluate IMA203 in 360 HLA-A*02:01-positive patients with second-line or later metastatic melanoma. The primary endpoint is median PFS. The trial is planned to commence in December 2024, with enrollment completion forecasted for 2026.
- Approval Timeline: The Company aims to submit a Biologics License Application (BLA) in early 2027. A pre-specified interim analysis is planned for early 2026.
- Manufacturing: A new ~100,000 square foot GMP facility is expected to start manufacturing in early 2025. The current facility will remain active until the end of 2025.
- Risks: The filing includes standard forward-looking statement disclaimers regarding clinical trial outcomes, regulatory approvals, manufacturing success rates, and economic conditions. All clinical data presented is preliminary.
Key Facts for Investor Verification
- Verify the specific manufacturing improvements (monocyte depletion or CD8/CD4 positive selection) that drove the PFS improvement from Phase 1a to Phase 1b.
- Confirm the timeline for the commencement of the SUPRAME Phase 3 trial in December 2024 and the projected enrollment completion in 2026.
- Monitor the status of the new GMP facility construction and its readiness to begin manufacturing in early 2025.
- Review the FDA's written post-meeting minutes regarding the RP2D and CMC package to ensure alignment with the company's stated trial design.
- Assess the financial runway required to support the Phase 3 trial and new facility operations, as no current cash position is disclosed in this filing.